Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

BioPharma Dive

The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.

pharminent June 11, 2026 (Last updated: June 11, 2026)

BioPharma Dive

The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.

Related Stories